Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLkZ21KSzVyPUCuNFAxPDV6IH7N MnHtV2FPT0WU
ES4 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMECwOlU{KG6P M{HUNHNCVkeHUh?=
ACHN NF\2dmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\QZ3pKSzVyPUCuNFAxQDh5IH7N NGTp[o9USU6JRWK=
KYSE-510 NGDxT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnRc29WUUN3ME2wMlAxODl5NTDuUS=> M1fOVHNCVkeHUh?=
EW-7 NIDu[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT3TWM2OD1yLkCwNlU5KG6P MVLTRW5ITVJ?
BFTC-905 NG\NTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TjXmlEPTB;MD6wNFUyPSCwTR?= MmK0V2FPT0WU
KE-37 NY\LSFkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33W[WlEPTB;MD6wNFU3OSCwTR?= MmHUV2FPT0WU
SBC-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSxTWM2OD1yLkCwOVchdk1? NX7IN4tEW0GQR1XS
NKM-1 NVfUOoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17BT2lEPTB;MD6wNFcxQSCwTR?= NVv2S2FEW0GQR1XS
RH-1 NYrOdZFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HQfWlEPTB;MD6wNFcyQCCwTR?= MYXTRW5ITVJ?
ALL-PO NV:xSIsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWwcoFKSzVyPUCuNFA5OyCwTR?= NH\LR|BUSU6JRWK=
QIMR-WIL NEPFNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEC4PVQhdk1? MnPVV2FPT0WU
A375 M2\mT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjyT2lrUUN3ME2wMlAxQTl3IH7N MUnTRW5ITVJ?
SIG-M5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j6TWlEPTB;MD6wNVA1KG6P NILa[3dUSU6JRWK=
KGN M{DzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHjTWM2OD1yLkCxNFghdk1? MkHkV2FPT0WU
EW-13 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEGxNkBvVQ>? M1LQdXNCVkeHUh?=
NCI-SNU-1 NYGxUFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\yPYg{UUN3ME2wMlAyPiCwTR?= M{TFZ3NCVkeHUh?=
PSN1 M3Xocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEG2OUBvVQ>? MUTTRW5ITVJ?
HUTU-80 NV3tc2ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MortTWM2OD1yLkCxOlYhdk1? MUHTRW5ITVJ?
EW-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW5TWM2OD1yLkCyN{BvVQ>? NF3tZVVUSU6JRWK=
786-0 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX2SXNnUUN3ME2wMlAzOyCwTR?= NFXoeGxUSU6JRWK=
ES1 NEH6bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomyTWM2OD1yLkCyOlghdk1? MUHTRW5ITVJ?
RKO M1Lpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnrco8zUUN3ME2wMlAzPzlibl2= MUjTRW5ITVJ?
ESS-1 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL5c3JKSzVyPUCuNFI5PiCwTR?= NXPwfG5tW0GQR1XS
SK-UT-1 M3XxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i5Z2lEPTB;MD6wNlk4KG6P Mn2zV2FPT0WU
LB2241-RCC M1TsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32zcmlEPTB;MD6wN|E5KG6P MWfTRW5ITVJ?
CHL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn6dZdKSzVyPUCuNFMzPCCwTR?= M1HYS3NCVkeHUh?=
SW1783 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSxPIxwUUN3ME2wMlA{OzZibl2= NEDhbnJUSU6JRWK=
MEL-JUSO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP1fG1KSzVyPUCuNFM6OSCwTR?= NH\td3ZUSU6JRWK=
HT-29 M1HSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMESxN{BvVQ>? Mo\hV2FPT0WU
SNG-M M{\0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV61UoNMUUN3ME2wMlA1OjVibl2= MWLTRW5ITVJ?
TE-15 NYLEcWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXqTWM2OD1yLkC0OlQhdk1? Mn[0V2FPT0WU
HOS M2PnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD1yLkC0PEBvVQ>? NYDUToJXW0GQR1XS
BB65-RCC NWGwTJpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf2[IdKSzVyPUCuNFUyOiCwTR?= NInjfldUSU6JRWK=
HCE-4 NIfacIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnWSGhHUUN3ME2wMlA2Ojhibl2= MX\TRW5ITVJ?
MHH-ES-1 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jacmlEPTB;MD6wOVMyKG6P NX\mfZdzW0GQR1XS
RPMI-7951 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXVWYRKSzVyPUCuNFU1OSCwTR?= NHvLXZlUSU6JRWK=
IST-SL2 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nlRmlEPTB;MD6wOVg1KG6P MkThV2FPT0WU
CMK NEfMTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DZN2lEPTB;MD6wOVg3KG6P M1n1RXNCVkeHUh?=
GR-ST MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[5TWM2OD1yLkC1PVUhdk1? MkXxV2FPT0WU
NALM-6 NWXoOY1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWwZVhJUUN3ME2wMlA3OjJibl2= NF\PO5ZUSU6JRWK=
RPMI-6666 M2XLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\wUpdlUUN3ME2wMlA3PTJibl2= MnuxV2FPT0WU
LC-2-ad NITFSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\qUmlEPTB;MD6wOlU{KG6P MVjTRW5ITVJ?
ARH-77 NGHPcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nWbWlEPTB;MD6wO|EyKG6P NWPRU3pmW0GQR1XS
IST-MEL1 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjCd5lKSzVyPUCuNFczPiCwTR?= M{\J[nNCVkeHUh?=
SW1710 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ROWlEPTB;MD6wO|UyKG6P M361Z3NCVkeHUh?=
DEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tjc2lEPTB;MD6wPFg4KG6P NHrzNXVUSU6JRWK=
AGS Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHhOmZKSzVyPUCuNFkxOiCwTR?= MYLTRW5ITVJ?
NCI-H2122 M{TYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEm0OkBvVQ>? MYXTRW5ITVJ?
HSC-4 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMUCyJI5O NIG3S5dUSU6JRWK=
AM-38 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfZVnpKSzVyPUCuNVIyKG6P NUXi[pdxW0GQR1XS
769-P M1fFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMUKzJI5O NVrLOoNJW0GQR1XS
RT-112 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMUK3JI5O NHjEOoRUSU6JRWK=
MCF7 M4XyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH6Zo9bUUN3ME2wMlE{PiCwTR?= MXjTRW5ITVJ?
IGROV-1 NEnrO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj6TphKSzVyPUCuNVQ2KG6P NFPi[HBUSU6JRWK=
OCI-AML2 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XRc2lEPTB;MD6xOFchdk1? NGLWboFUSU6JRWK=
NCI-H1299 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4TWM2OD1yLkG1O{BvVQ>? NUHzdGNuW0GQR1XS
A431 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDJTWM2OD1yLkG4N{BvVQ>? Mk\TV2FPT0WU
SW982 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX4fY5GUUN3ME2wMlIyOyCwTR?= M1HKZ3NCVkeHUh?=
BB30-HNC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XrWWlEPTB;MD6yN|Ehdk1? MWfTRW5ITVJ?
ACN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XJdWlEPTB;MD6yOFQhdk1? MULTRW5ITVJ?
647-V MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HRbmlEPTB;MD6yOFghdk1? NUm5eHh2W0GQR1XS
SK-PN-DW MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojuTWM2OD1yLkK2OkBvVQ>? NFr2N5ZUSU6JRWK=
LCLC-97TM1 NVu0dlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP4cnpKSzVyPUCuNlY4KG6P NHHSVldUSU6JRWK=
LB1047-RCC NInqOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;JZldXUUN3ME2wMlI3QSCwTR?= M360ZXNCVkeHUh?=
A2780 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTifFVKSzVyPUCuNlchdk1? NUT6[I91W0GQR1XS
C-33-A NIPv[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfRTWM2OD1yLkK3N{BvVQ>? MYPTRW5ITVJ?
NCI-H2228 NFHzSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzhTWM2OD1yLkOxOEBvVQ>? MorXV2FPT0WU
TE-5 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC2TWM2OD1yLkOxOkBvVQ>? NXzQcGs3W0GQR1XS
HC-1 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDOTWM2OD1yLkOyO{BvVQ>? M1ntb3NCVkeHUh?=
SK-MES-1 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;NbmlEPTB;MD6zNlghdk1? Mo\YV2FPT0WU
NCI-H1355 M3e4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXiyeWFvUUN3ME2wMlM5OSCwTR?= MlviV2FPT0WU
YKG-1 Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfRPJJKSzVyPUCuOFE6KG6P NUDYVpk3W0GQR1XS
RS4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHPTWM2OD1yLkSzN{BvVQ>? MVTTRW5ITVJ?
Daoy MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\k[5hKSzVyPUCuOFU3KG6P MWDTRW5ITVJ?
A3-KAW NEDLTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrUVFBFUUN3ME2wMlU2OSCwTR?= M4nQUnNCVkeHUh?=
SK-MEL-30 NG\rZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj3dpRUUUN3ME2wMlU2PCCwTR?= MWTTRW5ITVJ?
U031 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwNU[1JI5O MWHTRW5ITVJ?
SK-LMS-1 M3:4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O1NmlEPTB;MD61O|ghdk1? NVz1VVV2W0GQR1XS
ES6 NHHRb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHU[Ws{UUN3ME2wMlU5PiCwTR?= NUT3b4NWW0GQR1XS
EoL-1-cell NUDmboxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;3Z5NKSzVyPUCuOlE3KG6P NWG1foVOW0GQR1XS
NCI-H2009 NXzvcFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vBbGlEPTB;MD62NVkhdk1? MXPTRW5ITVJ?
A4-Fuk MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHYTWM2OD1yLk[yOkBvVQ>? Ml;rV2FPT0WU
KYSE-270 NGnvRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfoUo9KSzVyPUCuOlM1KG6P M2fCb3NCVkeHUh?=
SK-LU-1 NVjnT4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDYTWM2OD1yLk[1OUBvVQ>? NUP5WXZ7W0GQR1XS
SW872 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHmSGVlUUN3ME2wMlc3PSCwTR?= M1G4eXNCVkeHUh?=
ES8 NXH2bGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXaTWM2OD1yLke4JI5O NI\zdFZUSU6JRWK=
G-402 NGjnTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6zSlVKSzVyPUCuO|g1KG6P M4fLW3NCVkeHUh?=
ATN-1 NHO3cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\hNopKSzVyPUCuPFA4KG6P M2LmVHNCVkeHUh?=
DoTc2-4510 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHSUHdKSzVyPUCuPVAyKG6P Mny3V2FPT0WU
MES-SA NUPhWFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP1TWM2OD1yLkmwOUBvVQ>? NF7P[2pUSU6JRWK=
SF268 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWTWM2OD1yLkmyO{BvVQ>? NGXnc2xUSU6JRWK=
SF539 NEn1dWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwMEKgcm0> NULnc2d2W0GQR1XS
NB69 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLuTWM2OD1zLkC1JI5O NYrPfIJtW0GQR1XS
8505C MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuzeZVKSzVyPUGuNFYhdk1? NXO2[JlHW0GQR1XS
CAL-12T Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe2fm5kUUN3ME2xMlA5KG6P M1nqOHNCVkeHUh?=
BHY NGfBVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Ht[GlEPTB;MT6xOEBvVQ>? NVPYOXlzW0GQR1XS
LB647-SCLC NIX1[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fiTGlEPTB;MT6xPEBvVQ>? NE\wPY5USU6JRWK=
CAL-62 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPlTWM2OD1zLkKyJI5O NV;USHkzW0GQR1XS
MEG-01 NFq5eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPkTWM2OD1zLkK3JI5O Mlz0V2FPT0WU
MG-63 NGT6VGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi5emRiUUN3ME2xMlM{KG6P NF\vb2hUSU6JRWK=
SW620 NUjEeGlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PBdWlEPTB;MT6zOUBvVQ>? MlX4V2FPT0WU
A388 NULiZ4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXIcHZtUUN3ME2xMlM3KG6P MnvKV2FPT0WU
BCPAP NF\WO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLLUIRKSzVyPUGuOFUhdk1? Mn;XV2FPT0WU
P30-OHK MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjHTYhKSzVyPUGuOFYhdk1? M{T0fXNCVkeHUh?=
Ca9-22 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nneWlEPTB;MT61OEBvVQ>? MVTTRW5ITVJ?
VMRC-RCZ MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5RohKSzVyPUGuOVQhdk1? MXPTRW5ITVJ?
LOXIMVI M2e0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwNjDuUS=> NXKyNVNqW0GQR1XS
L-540 NFXqOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXCZ4xKSzVyPUGuOkBvVQ>? MmXqV2FPT0WU
NTERA-S-cl-D1 M17pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj2V2pGUUN3ME2xMlY1KG6P MV\TRW5ITVJ?
MFH-ino NEXvTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;6WmlEPTB;MT62OkBvVQ>? NHzlb|hUSU6JRWK=
Calu-6 M3zVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjod5lKSzVyPUGuO|Mhdk1? NV:yRnBuW0GQR1XS
HEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwN{mgcm0> NYW4NWMzW0GQR1XS
CAL-33 NUPqdnBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjBZmV6UUN3ME2xMlg6KG6P M3nQfXNCVkeHUh?=
HSC-3 NVTXZmc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwOUGgcm0> M{P0WnNCVkeHUh?=
KU812 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjJV21KSzVyPUGuPVEhdk1? M2TS[3NCVkeHUh?=
EB2 M1q2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[4eHhKSzVyPUKuNFEhdk1? MX;TRW5ITVJ?
SR Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwMUKgcm0> MoPvV2FPT0WU
NCI-H2087 M{fB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILuRm5KSzVyPUKuNVQhdk1? M3jPTXNCVkeHUh?=
H4 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\FTIF7UUN3ME2yMlE5KG6P NVzmTm17W0GQR1XS
EW-1 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwMkKgcm0> Mk[0V2FPT0WU
MC-IXC NFvmcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknaTWM2OD1{LkK2JI5O MX;TRW5ITVJ?
NCI-H727 M1HxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH5TWM2OD1{LkWxJI5O NX;mWGU1W0GQR1XS
MRK-nu-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3E[WxKSzVyPUKuOVchdk1? Ml\nV2FPT0WU
COLO-668 NWD6eYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLN[GJKSzVyPUKuOlYhdk1? NX\sWG42W0GQR1XS
CGTH-W-1 M2mwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnoSoUyUUN3ME2yMlczKG6P NFO4W2tUSU6JRWK=
CHP-212 NW\IWIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ixNGlEPTB;Mj63OUBvVQ>? NFLBV3lUSU6JRWK=
GI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKwRoJyUUN3ME2yMlc3KG6P MlrsV2FPT0WU
HCC1806 NYf6[nBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf4cFhEUUN3ME2yMlkyKG6P M2P4W3NCVkeHUh?=
HLE NFTqcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHnSVMxUUN3ME2zJI5O NH7lbGdUSU6JRWK=
HSC-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwMEOgcm0> M{fkWHNCVkeHUh?=
DMS-273 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXPW2I5UUN3ME2zMlA4KG6P M3OwZ3NCVkeHUh?=
DU-4475 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNwMUSgcm0> NYHU[W9tW0GQR1XS
LXF-289 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZfHZHUUN3ME2zMlMyKG6P M2DlW3NCVkeHUh?=
PANC-03-27 NEf6cIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH3VodKSzVyPUOuOVEhdk1? NH7CRZVUSU6JRWK=
GAMG NFqw[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LkdmlEPTB;Mz63OEBvVQ>? NXHjblJQW0GQR1XS
NCI-H522 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K4WmlEPTB;ND6zOEBvVQ>? MYfTRW5ITVJ?
SW626 M1T6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjVTWM2OD12LkS2JI5O MmWyV2FPT0WU
HT-144 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nDWmlEPTB;ND65NkBvVQ>? Mom3V2FPT0WU
MEL-HO NUXmOndPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETiWYZKSzVyPUWuNVYhdk1? MX7TRW5ITVJ?
BE-13 NXH4WHRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofvTWM2OD13LkKxJI5O NYnUT4tRW0GQR1XS
VA-ES-BJ MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ZTWM2OD13LkK2JI5O MYnTRW5ITVJ?
NCI-H441 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTVwNjDuUS=> Mni0V2FPT0WU
KP-4 NEXWO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDcpNkUUN3ME21MlYyKG6P M3GyWnNCVkeHUh?=
LoVo MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTVwN{Ggcm0> NHXTVo9USU6JRWK=
HT-1080 NWLzPZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33SVmlEPTB;NT64N{BvVQ>? NYnBS3ZKW0GQR1XS
GB-1 NWLhS4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DLOWlEPTB;NT64OEBvVQ>? M3fhb3NCVkeHUh?=
IA-LM MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHRZ5lKSzVyPUWuPVEhdk1? M323cHNCVkeHUh?=
8-MG-BA M1vOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKyTWM2OD13LkmzJI5O MlW4V2FPT0WU
SK-HEP-1 MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD14LkG0JI5O NF[4cXZUSU6JRWK=
697 NUSwfoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vxUWlEPTB;Nj6yOUBvVQ>? NEDnb4dUSU6JRWK=
KYSE-450 NEXrdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV62PXh2UUN3ME22MlMzKG6P MonwV2FPT0WU
HCC2998 NWDOfohwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\n[lFJUUN3ME22MlM1KG6P MlPCV2FPT0WU
HD-MY-Z MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfiPFZKSzVyPU[uOlghdk1? NXj5cpNtW0GQR1XS
OS-RC-2 M{O1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\QdXdKSzVyPU[uOlghdk1? MXfTRW5ITVJ?
SF126 NF\CdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfSTWM2OD15LkC1JI5O NULUXG93W0GQR1XS
Ca-Ski M3jIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LYSWlEPTB;Nz6wPUBvVQ>? MXXTRW5ITVJ?
NCI-H358 M4\YSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTNUYE6UUN3ME23MlE3KG6P MYrTRW5ITVJ?
J82 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXxTWM2OD15LkSxJI5O NWn5ZWE4W0GQR1XS
NCI-H2342 NFvMSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz3NXpKSzVyPUeuOlMhdk1? NFfqWpBUSU6JRWK=
OVCAR-8 MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\se5dKSzVyPUeuPUBvVQ>? NEjj[VdUSU6JRWK=
TE-8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X5RmlEPTB;ODDuUS=> NXrabYo5W0GQR1XS
ETK-1 NV7V[|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRThwMEigcm0> MUDTRW5ITVJ?
HAL-01 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnYRW9KSzVyPUiuNkBvVQ>? Mm[wV2FPT0WU
KYSE-150 M1X2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0ZmVKSzVyPUiuOFchdk1? M3rVPHNCVkeHUh?=
NCI-H810 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLLOXZuUUN3ME24MlU3KG6P NW[3dYQxW0GQR1XS
ONS-76 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmzPJRMUUN3ME24MlY5KG6P MlGzV2FPT0WU
NMC-G1 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRThwN{[gcm0> M2nXdXNCVkeHUh?=
C3A NUexdGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7JfXdWUUN3ME24Mlg1KG6P MmH4V2FPT0WU
PA-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHaTWM2OD16Lkm5JI5O NVLPbnhbW0GQR1XS
SH-4 NEfnemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNb3MxUUN3ME25MlAzKG6P NYL5[lVMW0GQR1XS
EFO-27 NWXrWIZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm1d3lKSzVyPUmuNFUhdk1? NIDxNo9USU6JRWK=
CAPAN-1 M2XWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTlwMkOgcm0> MVvTRW5ITVJ?
DU-145 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPER3B7UUN3ME25MlI6KG6P M{Xne3NCVkeHUh?=
A101D MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[yfmNVUUN3ME25MlM4KG6P M4HMbnNCVkeHUh?=
ST486 NFviUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID2XodKSzVyPUmuOFEhdk1? NV\yPIFHW0GQR1XS
NCI-H1437 M3rBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonCTWM2OD17LkSyJI5O NVmxW3JbW0GQR1XS
HGC-27 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL0VXp4UUN3ME25MlYhdk1? NEfNcVVUSU6JRWK=
8305C MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTlwNkSgcm0> MYPTRW5ITVJ?
OCUB-M Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPBWZhJUUN3ME2xNE4xOyCwTR?= M3rQfnNCVkeHUh?=
COLO-679 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXJTWM2OD1zMD6wO{BvVQ>? NEXG[Y1USU6JRWK=
Detroit562 NV3xTndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjLR2R1UUN3ME2xNE41OiCwTR?= NHfiV|RUSU6JRWK=
A204 NGLCRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFzLkG2JI5O NXu0coFkW0GQR1XS
NCI-H1734 M{W1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFzLkK5JI5O NIC2S5hUSU6JRWK=
MC-CAR NUSzVZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFzLkW4JI5O NU[0cndzW0GQR1XS
NCI-H2170 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7wTWM2OD1zMT65O{BvVQ>? NFiwc5RUSU6JRWK=
NCI-SNU-5 NXjDV3c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGzNXhmUUN3ME2xNk4yOyCwTR?= M2HBPXNCVkeHUh?=
HCE-T M{PCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;qTWM2OD1zMj60NkBvVQ>? NXLhcYtyW0GQR1XS
KYSE-180 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rYc2lEPTB;MUKuPFEhdk1? NXXMe|ZLW0GQR1XS
C8166 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DTfWlEPTB;MUOuNFghdk1? M{X4NHNCVkeHUh?=
NCI-H460 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zjbmlEPTB;MUOuOVQhdk1? NIX6TYlUSU6JRWK=
SNU-449 NF;TTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj6dVVDUUN3ME2xN{44PyCwTR?= MlW4V2FPT0WU
MDA-MB-468 NYjOeGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW1NZNKSzVyPUG0MlEzKG6P NIiyRpNUSU6JRWK=
COR-L23 NUT0dpptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP2TWM2OD1zND6xN{BvVQ>? NV\0fFRjW0GQR1XS
CTV-1 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTmTWM2OD1zND6xOEBvVQ>? MnHQV2FPT0WU
BL-41 NILnRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC4TWM2OD1zND6zO{BvVQ>? M1W0THNCVkeHUh?=
IGR-1 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HWVmlEPTB;MUSuOFIhdk1? NUTiVJJIW0GQR1XS
TK10 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W0WmlEPTB;MUSuOFkhdk1? MkTWV2FPT0WU
REH NX;wVnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfxe|VvUUN3ME2xOE42OSCwTR?= M1zEcnNCVkeHUh?=
LU-139 NIm1XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF2LkW5JI5O MXvTRW5ITVJ?
KP-N-YS MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7OOYRKUUN3ME2xOE46PyCwTR?= NGfrU|hUSU6JRWK=
PANC-10-05 M1Wyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTUcHVKSzVyPUG1MlM5KG6P MXnTRW5ITVJ?
HL-60 M4r3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGwTWM2OD1zNT62PUBvVQ>? NUXUcoRzW0GQR1XS
T84 NX;veVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTJTWM2OD1zNT65OkBvVQ>? MVTTRW5ITVJ?
RPMI-8226 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXMcFlKSzVyPUG2MlAzKG6P M1:4RXNCVkeHUh?=
UM-UC-3 NV;pdJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL2TWM2OD1zNj6xOkBvVQ>? MlHNV2FPT0WU
TE-10 M4LrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGxW3lKSzVyPUG2MlIyKG6P MlvRV2FPT0WU
CAL-148 NYHJc2pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r0RmlEPTB;MUeuNlMhdk1? NGLlXXhUSU6JRWK=
BV-173 NUnLUYRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjyUHFKSzVyPUG3MlI4KG6P M1;zXXNCVkeHUh?=
Calu-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr1WINKSzVyPUG3MlI6KG6P NETITI1USU6JRWK=
RPMI-2650 M3S3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX1TWM2OD1zNz61PUBvVQ>? NXX3dnE1W0GQR1XS
MKN45 M373cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfB[phKSzVyPUG3Mlc{KG6P MWrTRW5ITVJ?
NUGC-3 M3rKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\pS2pKSzVyPUG4MlM1KG6P MnXhV2FPT0WU
NCI-H520 NVHveHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\EdWlEPTB;MUiuO|chdk1? M3SzWXNCVkeHUh?=
CCRF-CEM MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr3TY9KSzVyPUG4Mlg2KG6P MUTTRW5ITVJ?
NCI-H2405 NHj1fWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF7LkGgcm0> NH;JV2dUSU6JRWK=
ES7 NYHJcItRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF7Lke2JI5O MmfuV2FPT0WU
BPH-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJyLkK4JI5O NWLKVVFQW0GQR1XS
SAS M1;y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJyLkWgcm0> MXTTRW5ITVJ?
HuCCT1 NW\IPHNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInGVJRKSzVyPUKwMlU5KG6P NF7Z[IdUSU6JRWK=
LOUCY NWLaVoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XrT2lEPTB;MkCuOlYhdk1? MkfVV2FPT0WU
NCI-H292 M4fVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1iyRmlEPTB;MkCuO|khdk1? NHvsRo1USU6JRWK=
G-361 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJzLkC3JI5O M13JUXNCVkeHUh?=
M059J NUXFeXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;IUmlEPTB;MkGuNFghdk1? M4nweHNCVkeHUh?=
NCI-H1651 M3f1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJzLkGxJI5O M{TWe3NCVkeHUh?=
KALS-1 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jnUmlEPTB;MkGuN|khdk1? M3PsNHNCVkeHUh?=
DJM-1 NYG3eXdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;PTWM2OD1{MT61PUBvVQ>? NF[0b5FUSU6JRWK=
AU565 M{W0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJzLkizJI5O NILKPJpUSU6JRWK=
HCC38 M4PiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvJTWM2OD1{MT65OUBvVQ>? MmLlV2FPT0WU
U251 M1zLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PP[mlEPTB;MkKuNlchdk1? NYm1UHd4W0GQR1XS
ABC-1 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[yTWM2OD1{Mj62OUBvVQ>? Mo\PV2FPT0WU
SK-NEP-1 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;FTpNKSzVyPUKyMlk{KG6P Mke4V2FPT0WU
CESS NXnoXZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnzO4JlUUN3ME2yN{4yQSCwTR?= M1u3UnNCVkeHUh?=
MIA-PaCa-2 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\OfmlEPTB;MkOuN|Yhdk1? M2PTPXNCVkeHUh?=
SUP-T1 NUfTU|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD1{Mz60O{BvVQ>? M4ntUnNCVkeHUh?=
L-428 M13IVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ|Lk[yJI5O M17FdXNCVkeHUh?=
SW954 NGe4NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHRemRKSzVyPUKzMlY5KG6P MVPTRW5ITVJ?
HO-1-N-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ|Lke3JI5O M{jUWnNCVkeHUh?=
CHP-126 M4fBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnFe3NKSzVyPUK0MlE1KG6P M{TacnNCVkeHUh?=
HMV-II NYm5XFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ2LkO0JI5O M{HTNXNCVkeHUh?=
NB10 M1vR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;SVGlEPTB;MkSuN|chdk1? MWHTRW5ITVJ?
A172 NHnyVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ2LkexJI5O NHrsSYRUSU6JRWK=
MONO-MAC-6 NFzMNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K0XWlEPTB;MkSuPFQhdk1? MWPTRW5ITVJ?
NCI-H1650 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XHSmlEPTB;MkWuOEBvVQ>? NFL5bFhUSU6JRWK=
NH-12 NF\mOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ3LkWgcm0> M1jUW3NCVkeHUh?=
ML-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ3Lke0JI5O M1HkWXNCVkeHUh?=
MZ2-MEL MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ4LkKyJI5O MnPjV2FPT0WU
COLO-684 NUjSbHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ4LkSxJI5O NU\FOYY2W0GQR1XS
HuP-T4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH61[pRKSzVyPUK3MlMhdk1? MVHTRW5ITVJ?
SW837 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PudWlEPTB;MkeuOlIhdk1? NEHPZWNUSU6JRWK=
MDA-MB-231 NXn2WG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzCTWM2OD1{Nz63PEBvVQ>? NGTqXXBUSU6JRWK=
KYSE-140 NUTRU3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXQfVFKSzVyPUK3MlkyKG6P MUPTRW5ITVJ?
NOMO-1 NFvTb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XvdWlEPTB;MkiuOlghdk1? NGr3bHlUSU6JRWK=
GP5d MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO5Om5KSzVyPUK4MlczKG6P NFLEXnhUSU6JRWK=
COR-L105 M1TzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfOSWtDUUN3ME2yPU41OiCwTR?= M1v0[nNCVkeHUh?=
LS-411N MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO5dohKSzVyPUK5Mlg5KG6P M2rFdnNCVkeHUh?=
NY MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnhc5NKSzVyPUOwMlE5KG6P NYLRWpF{W0GQR1XS
NCI-H2030 NX3D[WFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnjd|NKSzVyPUOwMlQ2KG6P NVXRWG5nW0GQR1XS
CCF-STTG1 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Lr[mlEPTB;M{GuOFIhdk1? M4rtNnNCVkeHUh?=
NCI-H1703 NYfWVpBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW1TWM2OD1|MT63PEBvVQ>? NF7t[otUSU6JRWK=
TUR NWC3TI1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnOTWM2OD1|Mj6wN{BvVQ>? M1TRUnNCVkeHUh?=
NOS-1 NILJTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTqfpBKSzVyPUOyMlQ1KG6P MWPTRW5ITVJ?
A2058 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LpdGlEPTB;M{KuPFMhdk1? MW\TRW5ITVJ?
LCLC-103H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33DPWlEPTB;M{OuNlUhdk1? NG\GemFUSU6JRWK=
NCI-H510A NEPrd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN|LkK3JI5O NHz2eFVUSU6JRWK=
BC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml65TWM2OD1|Mz63O{BvVQ>? M3LwNXNCVkeHUh?=
SK-CO-1 M4Cwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN2LkCxJI5O M2jPSXNCVkeHUh?=
A673 NFHFTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;YcWlEPTB;M{SuNVchdk1? MXnTRW5ITVJ?
VM-CUB-1 NX7pSFhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG0TWM2OD1|ND62PUBvVQ>? NXrmdVFvW0GQR1XS
HH NGSwV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC2[WVKSzVyPUO1MlA3KG6P NYXKTI5RW0GQR1XS
CAL-27 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHycGNKSzVyPUO1MlE3KG6P MX7TRW5ITVJ?
NEC8 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN3LkO3JI5O MVLTRW5ITVJ?
BxPC-3 NEHyOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXSRmlKSzVyPUO2MlkyKG6P MYLTRW5ITVJ?
SNB75 NGToN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jtTmlEPTB;M{euNlQhdk1? MmLuV2FPT0WU
NB13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTN6LkKzJI5O M1PiSnNCVkeHUh?=
SK-OV-3 NVm1Z45zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN6Lke0JI5O M2\CdHNCVkeHUh?=
ME-180 M32xUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L6T2lEPTB;M{iuPEBvVQ>? NF\CUpJUSU6JRWK=
JiyoyeP-2003 NWXGfm5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3flXWlEPTB;M{muN|ghdk1? NGXiUItUSU6JRWK=
LU-134-A Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzYNYxKSzVyPUSwMlAzKG6P MlvnV2FPT0WU
LS-123 NVjZV2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD12MD6yPEBvVQ>? M1jkSHNCVkeHUh?=
COLO-800 M4\xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjXU2tKSzVyPUSwMlU3KG6P NXLHRmZSW0GQR1XS
LB831-BLC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;5Om0yUUN3ME20NU45PSCwTR?= MXrTRW5ITVJ?
NCI-H747 NXHMeJBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR{LkK4JI5O MXrTRW5ITVJ?
MZ7-mel MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rST2lEPTB;NEKuOlYhdk1? NUm0RYlkW0GQR1XS
GT3TKB Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3yTIhKSzVyPUSyMlczKG6P NFH4S4lUSU6JRWK=
MOLT-16 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR|LkC1JI5O MlH0V2FPT0WU
23132-87 M4KwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j5WmlEPTB;NEOuNFUhdk1? NH;JOIpUSU6JRWK=
PF-382 NX7INoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHwXoxKSzVyPUS0MlIzKG6P NY\5NGE3W0GQR1XS
ES3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTR2Lk[gcm0> NXfUem9HW0GQR1XS
SW756 NF;2SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfCc5RCUUN3ME20OU4yPCCwTR?= NFPjeINUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID